<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255264</url>
  </required_header>
  <id_info>
    <org_study_id>2019-04046</org_study_id>
    <nct_id>NCT04255264</nct_id>
  </id_info>
  <brief_title>Adipose Inflammation and Diabetes (FAB)</brief_title>
  <acronym>FAB</acronym>
  <official_title>Adipose Tissue Inflammation and Diabetes Development (Fettvävsinflammation Och Diabetesutveckling)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates whether the addition of resolution molecules can inhibit inflammation
      and insulin resistance in human tissue taken from obese individuals, and whether the results
      of these studies correlate with patient-specific resolution phenotypes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory status</measure>
    <time_frame>2025</time_frame>
    <description>The inflammatory status will be studied in obese patients.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Obese</condition>
  <arm_group>
    <arm_group_label>Study patients</arm_group_label>
    <description>Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients participating in this study must have undergone a gastric bypass surgery &gt;2
        years ago, and currently have excess skin of &gt; 3 cm, thus requiring an abdominoplasty
        surgery. We only include patients that are obese (BMI 30-40 kg/m2). Patients interested in
        participating in the study donate the skin and adipose tissue that is discarded during
        surgery. In addition, they donate blood samples prior to surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 30-40 kg/m2

          -  Ptos (i.e. excess skin) &gt; 3 cm

          -  Patient underwent gastric bypass surgery &gt;2 years ago

          -  Patient has had a stable weight ≥6 months at the time of operation

          -  Patient does not smoke (min 6 weeks prior to surgery)

        Exclusion Criteria:

          -  Patients who do not understand spoken and written Swedish

          -  American Society of Anesthesiologists (ASA) classification ≥ 3

          -  Neurological, orthopedic or rheumatologic injury or illness affecting physical ability

          -  Preoperatively known hernia requiring surgical operation

          -  Severe mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Emma Borgeson, PhD</last_name>
    <phone>+46313420000</phone>
    <email>emma.borgeson@wlab.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Biörserud, RN, PhD</last_name>
    <phone>+46313420000</phone>
    <email>christina.biorserud@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska university hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Vastra Gotaland</state>
        <zip>40530</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Borgeson, PhD</last_name>
      <phone>+4631342000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

